WARNING: FETAL TOXICITY
When pregnancy is detected, discontinue Tekturna as soon as possible. (5.1)
Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (5.1)
Aliskiren, the active component of Tekturna ® Tablets, is an orally active, nonpeptide, potent renin inhibitor. Aliskiren is present in Tekturna Tablets as its hemifumarate salt.
Tekturna ® (aliskiren) is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. Use with maximal doses of ACE inhibitors has not been adequately studied.
Media Articles Related to Tekturna (Aliskiren)
Combination Therapy Improves Pulmonary Hypertension Outcomes
Source: Medscape Medical News Headlines [2016.05.20]
Combination therapy reduces the risk of clinical worsening in idiopathic and connective-tissue-associated pulmonary arterial hypertension better than monotherapy, according to a new meta-analysis.
Medscape Medical News
Hypertension in Pregnancy Ups Intellectual Disability, ASD Risk
Source: Medscape Psychiatry & Mental Health Headlines [2016.05.19]
Children born of mothers who have any form of hypertension during pregnancy are at elevated risk for intellectual disability and autism.
Medscape Medical News
American Society of Hypertension (ASH) 2016 Annual Scientific Meeting
Source: theheart.org | Medscape Cardiology Headlines [2016.05.17]
Read clinically focused news coverage of key developments from ASH 2016.
theheart.org on Medscape
Around-the-clock monitoring may unmask hypertension in African-Americans
Source: Hypertension News From Medical News Today [2016.05.17]
Ambulatory blood pressure monitoring, a device which measures blood pressure around-the-clock may help identify African Americans who have "masked" or undetected high blood pressure.
High Blood Pressure (Hypertension): Warning Signs, Risks, Medications
Source: MedicineNet Nosebleed Specialty [2016.05.13]
Title: High Blood Pressure (Hypertension): Warning Signs, Risks, Medications
Created: 3/9/2011 12:10:00 PM
Last Editorial Review: 5/13/2016 12:00:00 AM
Published Studies Related to Tekturna (Aliskiren)
Effect of naproxen and acetaminophen on blood pressure lowering by ramipril,
valsartan and aliskiren in hypertensive patients. 
CONCLUSIONS: Both naproxen and acetaminophen can affect anti-hypertensive therapy
Aliskiren effect on plaque progression in established atherosclerosis using high
resolution 3D MRI (ALPINE): a double-blind placebo-controlled trial. 
CONCLUSIONS: MRI quantification of atheroma plaque burden demonstrated that
Comparison of the effects of aliskiren/valsartan in combination versus valsartan
alone in patients with stage 2 hypertension. 
The extent to which the combination of a renin inhibitor with an angiotensin
receptor blocker (ARB) lowers clinic and ambulatory blood pressure (BP) versus an
ARB alone in stage 2 hypertension is not well known. Hence, we performed an
8-week, randomized, double-blind study in 451 patients with stage 2 hypertension
to compare the efficacy of the combination of aliskiren/valsartan 300/320 mg
versus valsartan 320 mg...
Long-Term Safety and Tolerability of the Oral Direct Renin Inhibitor Aliskiren with Optional Add-On Hydrochlorothiazide in Patients with Hypertension: A Randomized, Open-Label, Parallel-Group, Multicentre, Dose-Escalation Study with an Extension Phase. [2011.10.13]
BACKGROUND: Most patients with hypertension will require combination therapy with at least two agents from different antihypertensive classes to achieve blood pressure (BP) control. Thiazide diuretics, such as hydrochlorothiazide (HCTZ), are widely used in combination therapy. The volume reduction with these agents stimulates the renin-angiotensin system (RAS), making RAS inhibitors such as the direct renin inhibitor aliskiren a logical choice for combination therapy with HCTZ. OBJECTIVE: The aim of this study was to investigate the long-term safety, tolerability and efficacy of the direct renin inhibitor aliskiren, with or without addition of the diuretic HCTZ... CONCLUSION: In patients with hypertension, long-term treatment with aliskiren, with or without add-on HCTZ, is well tolerated and provides effective BP lowering that is sustained over 12 months. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT00219037.
Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study. [2011.10.01]
BACKGROUND: Hypertension frequently coexists with diabetes mellitus, resulting in increased cardiovascular risk. Thus, BP control is crucial in decreasing morbidity and mortality in this difficult-to-treat patient population. OBJECTIVE: The objective of this study was to evaluate the efficacy and safety of aliskiren in hypertensive patients with diabetes not adequately responsive to the combination of valsartan and hydrochlorothiazide (HCT)... CONCLUSION: The reductions in BP with aliskiren added to valsartan/HCT in this study were numerically greater compared with placebo added to valsartan/HCT, although not statistically significant. TRIAL REGISTRATION: ClinicalTrials.gov identifier NCT00219102.
Clinical Trials Related to Tekturna (Aliskiren)
Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension [Terminated]
Part 1 determined: aliskiren, amlodipine and angiotensin II concentrations in interstitial
fluid of fat and skeletal muscle; aliskiren and angiotensin II concentrations, and renin
activity and concentration in fat and skeletal muscle tissues (biopsies); aliskiren,
amlodipine and angiotensin II concentrations, and renin activity and concentration in
Part 2 investigated the potential for aliskiren to modulate renin-angiotensin-aldosterone
system (RAAS) activity, and lipid/carbohydrate metabolism in adipose and skeletal muscle
tissue in obese patients with hypertension in comparison to amlodipine.
Vitamin D Augmentation of Tekturna (Aliskiren) in Hypertension [Recruiting]
In this research study, the goal is to find out if a currently FDA-approved medication
called Tekturna(Aliskiren) along with the addition of Vitamin D will lower blood pressure
and improve heart function in the African American population. High blood pressure occurs
earlier in life in African Americans, is more severe, and is associated with greater organ
damage in relation to uncontrolled hypertension. Having low levels of Vitamin D is also very
common in the African American population. Research has shown that there may be a link
between low Vitamin D levels and the ability of high blood pressure medications to be fully
The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis [Terminated]
We will study the hypothesis that long-term Tekturna treatment will improve endothelial
function and the production and function of endothelial progenitor cells (EPCs) in patients
with early atherosclerosis. Specifically, long-term Tekturna treatment will increase the
Reactive Hyperemia Peripheral Arterial Tonometry indexes and increase the numbers and the
function of circulating endothelial progenitor cells, compared to placebo, in association
with a reduction in inflammation and oxidative stress.
A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus [Completed]
The study objective was to assess the effect of single and multiple doses of aliskiren on
renal plasma flow, glomerular filtration rate and to compare the effects of single and
multiple doses of aliskiren versus captopril or irbesartan on renal blood flow, glomerular
filtration rate, and retinal blood flow in patients with type 2 diabetes mellitus.
Pharmacokinetics, Safety and Tolerability of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy Subjects [Completed]
This study will assess the pharmacokinetics, safety and tolerability of aliskiren in healthy
subjects and patients with End Stage Renal Disease on hemodialysis.
Reports of Suspected Tekturna (Aliskiren) Side Effects
Blood Pressure Increased (33),
Drug Ineffective (21),
Cerebrovascular Accident (19),
Diabetes Mellitus (16),
Blood Pressure Inadequately Controlled (14),
Blood Pressure Fluctuation (13), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Tekturna has an overall score of 10. The effectiveness score is 10 and the side effect score is 8. The scores are on ten point scale: 10 - best, 1 - worst.
Tekturna review by 49 year old female patient
|Overall rating:|| || |
|Effectiveness:|| || Highly Effective|
|Side effects:|| || Mild Side Effects|
|Condition / reason:|| || hypertension|
|Dosage & duration:|| || 300mg taken once per day for the period of 2 years|
|Other conditions:|| || high cholesterol|
|Other drugs taken:|| || terazosin, Niaspan|
|Benefits:|| || Very well managed blood pressure within normal, healthy range. I had an allergic reaction to a more common blood pressure medication, Lisinopril (which is a combination of a thiazide diuretic and an ACE inhibitor). The newer Tekturna has worked perfectly for me with only the slightest dizziness when I rose too quickly early on, but no side effects at all after the first few weeks.|
|Side effects:|| || I had a very slight issue, early on in treatment (in the first few weeks only), of slight dizziness when rising quickly from either laying down or from bending over with my head down (such as when petting my cat when she was laying on the floor), but that fully resolved quite quickly. I have not had any other side effects at all. |
|Comments:|| || I take one 300mg Tekturna per day, in the morning, along with 10mg of Terazosin (Hytrin) and my blood pressure is wonderfully under control. My last blood pressure reading was 110/66 which is perfect!|
Page last updated: 2016-05-20